GlassScriptPhysician profile
Amanda Paternostro
NPI 1962899963
$762.68
in general payments reported to CMS, 2019-2025
13 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $190 · 2023: $45.96 · 2024: $241 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $470.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $276.89 | 2024-2025 | Nexplanon |
| Lupin INC. | $97.52 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.03 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $58.97 | 2019-2020 | |
| Coopersurgical, INC. | $44.62 | 2020-2025 | Paragard T 380a, Paragard T 380a |
| Mylan Pharmaceuticals INC. | $33.41 | 2019-2020 | |
| Sanofi Pasteur INC. | $32.87 | 2025 | |
| Hologic Sales and Service, LLC | $29.00 | 2024 | Aptima |
| Astellas Pharma US INC | $25.83 | 2025 | Veozah |
| Nevro Corp. | $21.98 | 2020 | |
| Abbvie INC. | $21.14 | 2019 | |
| Zyla Life Sciences, INC. | $15.77 | 2020 | |
| Pfizer INC. | $15.65 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Paternostro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.